Clinical Trial Update: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy [Phase 1, Phase 2]

View source ↗

Summary

Recruitment is ongoing for a Phase 1/2 study of the radiopharmaceutical [212Pb]VMT-alpha-NET targeting somatostatin receptors in metastatic or inoperable somato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neuroendocrine Tumor
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• [212Pb]VMT-alpha-NET (212Pb-VMT-alpha-NET)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors | Phase 1, Phase 2 | Status: RECRUITING